NanJing Pharmaceutical Company Limited reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 40,546.78 million compared to CNY 37,436.17 million a year ago. Revenue was CNY 40,546.78 million compared to CNY 37,436.17 million a year ago.

Net income was CNY 440.3 million compared to CNY 470.24 million a year ago. Basic earnings per share from continuing operations was CNY 0.34 compared to CNY 0.38 a year ago. Diluted earnings per share from continuing operations was CNY 0.34 compared to CNY 0.38 a year ago.